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Magnesium Sulfate in Aneurysmal
Subarachnoid Hemorrhage
A Randomized Controlled Trial
Walter M. van den Bergh; on behalf of the MASH Study Group
Background and Purpose—Magnesium reverses cerebral vasospasm and reduces infarct volume after experimental
subarachnoid hemorrhage (SAH) in rats. We aimed to assess whether magnesium reduces the frequency of delayed
cerebral ischemia (DCI) in patients with aneurysmal SAH.
Methods—Patients were randomized within 4 days after SAH. Magnesium sulfate therapy consisted of a continuous
intravenous dose of 64 mmol/L per day, to be started within 4 days after SAH and continued until 14 days after occlusion
of the aneurysm. The primary outcome DCI (defined as the occurrence of a new hypodense lesion on computed
tomography compatible with clinical features of DCI) was analyzed according to the “on-treatment” principle. For the
secondary outcome measures “poor outcome” (Rankin 3) and “excellent outcome” (Rankin 0), we used the
“intention-to-treat” principle.
Results—A total of 283 patients were randomized. Magnesium treatment reduced the risk of DCI by 34% (hazard ratio,
0.66; 95% CI, 0.38 to 1.14). After 3 months, the risk reduction for poor outcome was 23% (risk ratio, 0.77; 95% CI,
0.54 to 1.09). At that time, 18 patients in the treatment group and 6 in the placebo group had an excellent outcome (risk
ratio, 3.4; 95% CI, 1.3 to 8.9).
Conclusions—This study suggests that magnesium reduces DCI and subsequent poor outcome, but the results are not yet
definitive. A next step should be a phase III trial to confirm the beneficial effect of magnesium therapy, with poor
outcome as primary outcome. (Stroke. 2005;36:1011-1015.)
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Because of its occurrence at young age and its often pooroutcome, the loss of productive life years from subarach-
noid hemorrhage (SAH) is as large as that from ischemic
stroke, the most frequent cause of stroke.1 Death or depen-
dence occurs in70% of patients and is attributed to delayed
cerebral ischemia (DCI) in approximately one third of all
patients with poor outcome.2,3
DCI occurs most frequently between 4 and 10 days after
the hemorrhage.4,5 Despite many years of research, the
effectiveness of treatment to prevent or reverse it is modest.6
The current mainstay of treatment is nimodipine and main-
taining normovolemia, but even with this strategy, DCI
occurs in 27% of patients. Reducing the frequency and
consequences of DCI will improve the outcome after SAH.
The interval between the bleeding and the onset of DCI
provides an opportunity for preventive treatment. This is a
major advantage compared with cerebral ischemia from a
thromboembolic event, in which neuroprotective agents can
only be given after the onset of ischemia.
Hypomagnesemia occurs in 50% of patients with SAH
and is related to the occurrence of DCI and poor outcome
after 3 months.7 Magnesium was shown to have a neuropro-
tective effect in numerous stroke models, and it reversed
cerebral vasospasm and reduced ischemic depolarization time
and infarct volume after experimental SAH in rats.8–10
Putative mode of actions of magnesium include inhibition of
the release of excitatory amino acids and blockade of the
N-methyl-D-aspartate–glutamate receptor.11,12 Magnesium is
also a noncompetitive antagonist of voltage-dependent cal-
cium channels and has a dilatatory effect on cerebral arteries.
Magnesium is readily available, inexpensive, and has a
well-established clinical profile in obstetrical and cardiovas-
cular practice.13,14 In the current study, we aimed to assess
whether intravenous magnesium sulfate, started within 4 days
after SAH onset, reduces the frequency of DCI in patients
with aneurysmal SAH.
Methods
Between November 2000 and January 2004, we enrolled patients in
the Magnesium and Acetylsalicylic acid in Subarachnoid Hemor-
rhage (MASH) trial. This study was a randomized, double-blind,
placebo-controlled multicenter trial with a factorial design: magne-
sium versus placebo and acetylsalicylic acid versus placebo. Only
the results of the magnesium part of the trial are presented here. The
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ethics committees of the participating hospitals approved the proto-
col of the trial.
Patients were included when they could be randomized within 4
days after aneurysmal SAH. The diagnosis of SAH was based on a
positive computed tomography (CT) scan or xanthochromia of
cerebrospinal fluid. Aneurysmal SAH was diagnosed if an aneurysm
was present on conventional or CT/magnetic resonance angiography
or if the CT scan showed a typical aneurysmal pattern of hemor-
rhage. If the CT scan was negative, xanthochromia of cerebrospinal
fluid with an aneurysm on angiography confirmed the diagnosis of
aneurysmal SAH. Exclusion criteria for the study were nonaneurys-
mal causes for SAH, renal failure (serum creatinin 150 mol/L),
age 18 years, no informed consent, or imminent death.
The clinical condition at admission was assessed with the World
Federation of Neurological Surgeons (WFNS) scale.15 A dichotomy
was made between good neurological condition (WFNS score I, II,
or III) and poor neurological condition (WFNS score IV or V) at
admission.
We assessed the amount of cisternal and ventricular blood on the
initial CT scan according to the method described by Hijdra et al.16
The sum scores of blood in the cisterns (range 0 to 30) and ventricles
(range 0 to 12) were dichotomized at their median value.
All patients were kept under close observation, with continuous
monitoring of blood pressure, heart rate, ECG, and arterial oxygen
saturation for at least 2 weeks after the onset of SAH. They were
treated according to a standardized protocol that consisted of
absolute bed rest until aneurysm treatment, administration of nimo-
dipine, cessation of antihypertensive medication, and intravenous
administration of fluid aiming for normovolemia. Recurrent bleeding
was defined as a sudden clinical deterioration with evidence of fresh
blood on a CT scan compared with a previous scan.
Interventions
Study medication was produced, randomized, and distributed by the
University Medical Center Utrecht and stored at all participating
centers. Magnesium sulfate therapy consisted of a continuous intra-
venous dose of 64 mmol/L per day, which started immediately after
randomization and continued until 14 days after occlusion of the
aneurysm, or for a maximum of 18 days after the onset of SAH when
aneurysm treatment was performed 4 days after SAH onset. The
placebo consisted of 50 mL of normal saline. The dose regime of
64 mmol/L per day was based on a dose finding study17 and aimed
at maintaining serum magnesium levels within the range of 1.0 to
2.0 mmol/L during magnesium treatment. Monitoring of serum
magnesium levels was not obligatory for the trial, but in 2 partici-
pating centers, magnesium measurements were part of clinical
management. The principal investigators of the trial remained
blinded for serum magnesium levels.
Outcomes
Because at this stage we aimed at preventing DCI rather than
improving overall outcome, the predefined primary outcome mea-
surement was the occurrence of DCI within 3 months after onset of
SAH. Three months after the SAH, we assessed functional outcome
with the modified Rankin Scale, a 6-point handicap scale that
focuses on restrictions in lifestyle, by means of a telephone inter-
view. The Rankin Scale, frequently used in stroke outcome research,
is easy to administer and reliable in terms of interobserver
agreement.18–20
Secondary predefined outcome measurements were: (1) occur-
rence of any new hypodensity on brain CT regardless of its cause; (2)
death or disability (poor outcome), defined as a Rankin score of 4 or
worse; and (3) nonexcellent outcome, defined as the proportion of
patients with a Rankin score of 1 or worse. With a Rankin score of
0 (excellent outcome), the patient is considered having no symptoms,
corresponding with a good quality of life.21
All CT scans made after SAH onset were analyzed for new
hypodensities by 3 members of the steering committee always in the
presence of the principal investigator (G.J.E.R.). All members of the
steering committee who scored the CT scans were blinded for
treatment allocation. Hypodensities on CT scan were classified
according to the presumed origin as follows: (1) representing
“spontaneous” cerebral ischemia; (2) caused by operation or endo-
vascular treatment; (3) associated with the initial hemorrhage,
usually an intracerebral hematoma; (4) caused by placement of a
ventricular catheter; and (5) other. The primary outcome was defined
as the occurrence of a new spontaneous hypodense lesion as revealed
by a CT scan compatible with clinical features of DCI (gradually
developed focal deficits, decreased level of consciousness, or both).
In case of uncertainty about the cause of postoperative hypodensities,
the report of the operation was reviewed. After weighing all data, the
committee came to a consensus. Patients with an uneventful clinical
course in which no control CT scan was made were scored as having
no new hypodensities.
Data Analysis
Trial design and conduct for the primary outcome DCI and for the
secondary outcome “any hypodensity on CT” were according to the
“on-treatment” principle. The secondary outcome measures “poor
outcome” and “nonexcellent outcome” were analyzed according to
the “intention-to-treat” principle.
According to the data of our pilot study,22 50% of patients in the
untreated group would have hypodense lesions on CT. Assuming
that intervention reduces this risk by 40% (30% risk of hypodense
lesions with magnesium treatment), with the usual 5% and
1-80%, 200 patients were needed.
The principal aim of the data analysis was to compare the
incidence of DCI between the 2 treatment groups. Because this is an
explanatory research question, we used an on-treatment analysis.
Kaplan–Meier graphs were used for graphical comparison. The risks
of DCI in the 2 groups were compared in terms of the hazard ratio
obtained from Cox proportional hazards modeling.23 The precision
of the hazard ratio estimates was described with 95% CIs, also
obtained from the Cox model.
To assess the effect of treatment on outcome at 3 months, we
estimated risk ratios (RRs) with corresponding 95% CIs. For this
clinical relevant outcome measurement, we used an intention-to-treat
analysis.
Results
Infusion of the trial medication was begun in all 283
randomized patients, and no patients were lost to follow-up
(Figure). No major side effects occurred (Figure legend).
Patients were well matched for baseline data, including
treatment of the aneurysm (Table 1).
In the explanatory, on-treatment analysis, magnesium
treatment reduced the risk of the primary outcome measure
DCI by 34% (hazard ratio, 0.66; 95% CI, 0.38 to 1.14), with
a number needed to treat (NNT) of 14 (Table 2). There was
no reduction of risk for the outcome event “any new hypo-
densities on CT, regardless of cause” (RR, 1.04; 95% CI, 0.79
to 1.37).
In the intention-to-treat analysis, the risk reduction for poor
outcome at 3 months was 23% (RR, 0.77; 95% CI, 0.54 to
1.09; NNT, 12). At that time, 18 patients in the treatment
group had an excellent outcome (Rankin grade 0) compared
with 6 patients in the placebo group. The relative risk for
excellent outcome was 3.4 (95% CI, 1.3 to 8.9; NNT 11). In
an intention-to-treat analysis of the primary outcome measure
DCI, the hazard ratio was 0.61 (95% CI, 0.36 to 1.04).
Discussion
This study suggests that magnesium reduces DCI and subse-
quent poor outcome in patients with SAH, but the results are
not yet definitive. The increase in excellent outcome in
patients treated with magnesium was statistically significant,
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but this predefined outcome measurement was not the pri-
mary aim of the analysis.
Although hypomagnesemia is associated with DCI and
poor outcome,7 we aimed at reaching therapeutic serum
magnesium levels instead of magnesium suppletion alone.
Because magnesium intoxication, manifested by nausea,
headache, and muscle weakness, can occur from levels of
2.0 mmol/L onward, our purpose was to maintain a serum
magnesium level within the range of 1.0 to 2.0 mmol/L
during magnesium treatment.
The result of our study is in line with the neuroprotective
effect attributed to magnesium in several animal studies and
small clinical trials.9,10,24,25 The only other randomized trial so
far showed that “clinical vasospasm,” defined as a new focal
neurological deficit that could not be accounted for by other
cause, occurred in 6 of 20 patients receiving magnesium
sulfate and in 5 of 16 patients receiving placebo (RR, 0.96;
95% CI, 0.36 to 2.6).26 Poor outcome occurred in 7 of 20
patients receiving magnesium sulfate and in 8 of 16 patients
receiving placebo (RR, 0.70; 95% CI, 0.32 to 1.5).
In our study, we chose to analyze DCI and not vasospasm
because vasospasm by itself does not always lead to DCI,
quite apart from the practical problems of measuring arterial
narrowing. However, prevention of DCI is only an indirect
measure for a beneficial effect of magnesium treatment. A
conclusive trial with functional recovery as primary outcome
measure would have required a larger number of patients. We
chose to start with an “explanatory” study with a proof-of-
concept design.27 For the primary outcome measurement,
regarding the explanatory research question, we used an
on-treatment analysis. Because on-treatment analysis is im-
proper for measuring the clinically more relevant effect on
outcome, we used intention-to-treat analysis instead. Unfor-
tunately, it turned out that we underpowered the study
because we used the strict criteria for DCI as primary
outcome measure rather than all hypodensities on CT scan-
ning. This reduced the frequency of the primary outcome in
the control group from the expected 50% (data pilot study)22
to 25%. Thanks to a relatively high inclusion rate, we could
increase the number of patients within the 3-year randomiza-
tion period from 200 to 283. The sizable proportion of
patients with a poor clinical condition on admission (24%)
indicates that this group of patients is well represented,
allowing generalization of our study results to patients with
SAH in general.
Our primary outcome measure did not include silent
infarctions; however, these were contained in the secondary
outcome measure “new hypodensities on CT.” We do not
consider it likely that many patients who had an uneventful
clinical course, and thereby no indication for a new CT scan,
would have had a silent infarct at their scan, had it been made.
Hence, we do not think that such additional scans, without a
clinical indication, would have had a major influence on this
secondary outcome. Moreover, we find the deterioration of
the patient resulting in CT scanning an important aspect of
the primary outcome measure because it already incorporates
elements that are important for the patient, elements that will
be taken into account to a greater extent in the primary
outcome “poor outcome” of the phase III clinical trial that we
have planned.
Given the supposed mode of action of magnesium treat-
ment, one might expect a benefit of magnesium treatment in
ischemic stroke. However, the recently published results of
the Intravenous Magnesium Efficacy in Stroke (IMAGES)
trial showed that magnesium given within 12 hours of acute
stroke did not reduce the risk of poor outcome.28 That
magnesium treatment might nevertheless be beneficial in
SAH is suggested by differences in pathophysiology and dose
regime. In the IMAGES trial, treatment was started within 12
hours after stroke onset; however, the majority of patients
received medication beyond 6 hours, with only 3% treated
within 3 hours. In ischemic stroke, this could mean that most
of the damage had already occurred. At the other end of the
time frame, treatment was maintained for only 24 hours.
However, the ischemic cascade continues for 24 hours.29
This leaves the possibility that secondary brain damage such
as apoptosis was not counteracted. Because magnesium plays
an important role in DNA stabilization, the potential benefi-
cial effects of magnesium may not have been used in this
manner. Although in our study population, the median start of
treatment was 28 hours, it was continued for at least 2 weeks.
Given the biphasic pattern of ischemia in SAH, it might be
possible to prevent secondary brain ischemia. The results of
our study suggest that prevention of ischemia with magne-
sium is more effective than treatment after onset of the
ischemic event. Extended use of magnesium sulfate is needed
to cover the period at risk for DCI.26
The risk reduction of magnesium is added to the risk
reduction already achieved with the routinely administrated
N-type calcium channel antagonist nimodipine. Nimodipine
reduces the proportion of patients with poor outcome and
ischemic neurological deficits after aneurysmal SAH.6 Be-
cause the actions of nimodipine and magnesium have an
Flow diagram of the progress through the phases of the trial.
We have no specified information on how many patients were
assessed for eligibility or the reasons why they were excluded
for randomization. Seventeen patients allocated to magnesium
treatment discontinued intervention for the following reasons: no
aneurysmal SAH (4); hypotension (1); phlebitis (2); bradycardia
and atrium fibrillation (1); routine magnesium suppletion (1);
hypermagnesemia (3); renal failure (1); death imminent (1);
request of patient or family (1); and unreliable registration of
treatment administration (2). Seventeen patients allocated to
saline treatment discontinued intervention for the following rea-
sons: no aneurysmal SAH (5); phlebitis (1); intracranial hema-
toma (1); trial medication lost (1); routine magnesium suppletion
(3); request of patient or family (2); and unreliable registration of
treatment administration (4).
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overlap, the protective effect of magnesium by itself shown in
this study may have been underestimated.
The results of this study suggest that magnesium reduces
ischemic complications after SAH and thereby may reduce
the risk of poor outcome after SAH, but as yet, the evidence
for the introduction of magnesium treatment in clinical
practice is inconclusive. A large phase III trial with “poor
outcome” as the primary measure of outcome should provide
final evidence for the effect of magnesium therapy in addition
to the standard therapy. On the basis of the results of this
study,1100 patients are needed, which makes it feasible for
an international trial to produce definitive results in just a few
years. Given the fact that magnesium is safe and inexpensive,
and has a small NNT30 in this phase II trial, even a small
absolute benefit would lead to an enormous cost saving for
health care services.
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TABLE 1. Baseline and Outcome Data According to Allocated Treatment
Total
n283
Intention to Treat
n283
On Treatment
n249
Magnesium Placebo Magnesium Placebo
Baseline data
No. randomized 283 139 144 122 127
Type of disease
Aneurysmal SAH (%) 274 (97) 135 (97) 139 (97) 122 (100) 127 (100)
Perimesencephalic SAH (%) 4 (1) 2 (1) 2 (1) - -
Other (%) 5 (2) 2 (1) 3 (2) - -
Mean age 54.6 54.8 54.4 54.4 54.5
Women (%) 184 (65) 87 (63) 97 (67) 78 (64) 89 (70)
Clinical condition at admission
WFNS I (%) 133 (47) 69 (50) 64 (44) 58 (48) 56 (44)
WFNS II (%) 68 (24) 30 (22) 38 (26) 28 (23) 33 (26)
WFNS III (%) 13 (5) 7 (5) 6 (4) 6 (5) 4 (3)
WFNS IV (%) 43 (15) 21 (15) 22 (15) 21 (17) 20 (16)
WFNS V (%) 26 (9) 12 (9) 14 (10) 9 (7) 14 (11)
WFNS 4 (%) 69 (24) 33 (24) 36 (25) 30 (25) 34 (27)
No. of patients with cisternal blood above median 23, (%) 171 (60) 82 (59) 89 (62) 76 (62) 81 (64)
No. of patients with ventricular blood above median 2, (%) 94 (33) 48 (35) 46 (32) 42 (34) 41 (32)
Intracranial hematoma amount (%) 14 (5) 7 (5) 7 (5) 5 (4) 4 (3)
Treatment aneurysm
Surgery (%) 155 (55) 72 (52) 83 (58) 66 (54) 74 (58)
Endovascular treatment (%) 74 (26) 39 (28) 35 (24) 35 (29) 32 (25)
None 54 (19) 28 (20) 26 (18) 21 (17) 21 (17)
Mean start study medication (h; median) (%) 35 (28) 35 (28) 35 (28) 33 (27) 35 (28)
Recurrent bleeding (%) 41 (15) 21 (15) 20 (14) 18 (15) 19 (15)
Outcome measurements
New hypodensities on CT (%) 128 (45) 62 (45) 67 (47) 56 (46) 56 (44)
DCI (%) 57 (20) 22 (16) 35 (24) 21 (17) 31 (24)
Poor outcome, Rankin 3 (%) 89 (31) 38 (27) 51 (35) 32 (27) 44 (35)
Excellent outcome, Rankin 0 (%) 24 (8) 18 (13) 6 (4) 14 (11) 4 (3)
TABLE 2. Outcomes in the Trial According to
Magnesium Treatment
RR (95% CI) NNT
Primary outcome
DCI* 0.66 (0.38–1.14)‡ 14 (35 NNTH to 6 NNTB)
Secondary outcomes
New hypodensities on CT* 1.04 (0.79–1.37) -
Poor outcome† 0.77 (0.54–1.09) 12 (37 NNTH to 5 NNTB)
Excellent outcome† 3.4 (1.3–8.9) 11 (7 NNTB to 43 NNTB)
*On-treatment analysis; †intention-to-treat analysis; ‡hazard ratio.
Poor outcome is defined as a Rankin score of 4 or worse; excellent outcome
is defined as a Rankin score of 0; this is a positive outcome, with an RR 1.
NNTB indicates No. needed to benefit 1 patient; NNTH, No. needed to treat
to harm 1 patient.30
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